Post-Prostatectomy Linac-Based Ultrahypofractionated Radiation Therapy for Patients With Localized Prostate Cancer

Official Title

Post-Prostatectomy Linac-Based Ultrahypofractionated Radiation Therapy for Patients With Localized Prostate Cancer: A Treatment Feasibility and Outcomes Study

Summary:

Radical prostatectomy is a common treatment for localized prostate cancer. More than 30% of men who undergo surgery will subsequently develop recurrence, particularly in patients with adverse features where the risk may be even higher. Recurrence typically manifests as a rise in serum-level of prostate-specific antigen (PSA), referred to as biochemical recurrence. Post-operative radiation therapy is a potentially curative option for many patients, as shown in multiple prior randomized studies. A standard course of post-operative radiation requires 6 to 6 and half weeks of treatment, 5 days a week; however, new high-precision radiation techniques with image guidance, termed stereotactic body radiation therapy (SBRT), can deliver an equivalent or higher dose of treatment in 5 visits. Our group, amongst others, have demonstrated in previous studies, that the new 5-treatment technique was safe, convenient and effective in patients with intact prostates. Currently, limited data exists on this approach after prostatectomy. This study will be one of the first to assess the side effect profile and efficacy of SBRT in patients with localized prostate cancer who are considered candidates for post-prostatectomy radiation.

Trial Description

Primary Outcome:

  • Acute genitourinary (GU) and gastrointestinal (GI) toxicities
Secondary Outcome:
  • Incidence of late GU and GI toxicities (≥6 months)
  • Biochemical disease-free survival (bDFS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society